Single ascending dose study of the safety, tolerability, and pharmacokinetics of GAP-134 administered intravenously as a 24-hour infusion to healthy subjects

Trial Profile

Single ascending dose study of the safety, tolerability, and pharmacokinetics of GAP-134 administered intravenously as a 24-hour infusion to healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2008

At a glance

  • Drugs Danegaptide (Primary)
  • Indications Arrhythmias
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 12 Mar 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2007 The expected completion date for this trial is now 31 Dec 2007.
    • 04 Oct 2007 Status change from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top